Fibronectin and colorectal cancer: signaling pathways and clinical implications

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Colorectal Cancer. Lancet. 2019;394(10207):1467–1480.
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–271.
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–548.
   PubMed Web of Science ®Google Scholar
• Taylor DP, Burt RW, Williams MS, et al. Population-based family history-specific risks for colorectal cancer: a constellation approach. Gastroenterology. 2010;138(3):877–885.
   PubMed Web of Science ®Google Scholar
• Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639–645.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Ben Q, Shen H, et al. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2011;26(11):863–876.
   PubMed Web of Science ®Google Scholar
• Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer. 2009;124(10):2406–2415.
   PubMed Web of Science ®Google Scholar
• Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol. 2011;22(9):1958–1972.
   PubMed Web of Science ®Google Scholar
• Sadanandam A, Lyssiotis CA, Homicsko K, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619–625.
   PubMed Web of Science ®Google Scholar
• De Sousa EMF, Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614–618.
   PubMed Web of Science ®Google Scholar
• Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87(2):159–170.
   PubMed Web of Science ®Google Scholar
• White ES, Muro AF. Fibronectin splice variants: understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life. 2011;63(7):538–546.
   PubMed Web of Science ®Google Scholar
• Park J, Schwarzbauer JE. Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene. 2014;33(13):1649–1657.
   PubMed Web of Science ®Google Scholar
• de Almeida PG, Pinheiro GG, Nunes AM, et al. Fibronectin assembly during early embryo development: a versatile communication system between cells and tissues. Dev Dyn. 2016;245(4):520–535.
   PubMed Web of Science ®Google Scholar
• Maione AG, Smith A, Kashpur O, et al. Altered ECM deposition by diabetic foot ulcer-derived fibroblasts implicates fibronectin in chronic wound repair. Wound Repair Regen. 2016;24(4):630–643.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ni H. Fibronectin maintains the balance between hemostasis and thrombosis. Cell Mol Life Sci. 2016;73(17):3265–3277.
   PubMed Web of Science ®Google Scholar
• Lin TC, Yang CH, Cheng LH, et al. Fibronectin in cancer: friend or foe. Cells. 2019;9(1):27.
   Web of Science ®Google Scholar
• Speziale P, Arciola CR, Pietrocola G. Fibronectin and its role in human infective diseases. Cells. 2019;8(12):1516.
   PubMed Web of Science ®Google Scholar
• Elices MJ, Tsai V, Strahl D, et al. Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature. J Clin Invest. 1994;93(1):405–416.
   PubMed Web of Science ®Google Scholar
• Cai X, Liu C, Zhang TN, et al. Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion. J Cell Biochem. 2018;119(6):4717–4728.
   PubMed Web of Science ®Google Scholar
• Xie Y, Liu C, Qin Y, et al. Knockdown of IRE1ɑ suppresses metastatic potential of colon cancer cells through inhibiting FN1-Src/FAK-GTPases signaling. Int J Biochem Cell Biol. 2019;114:105572.
   PubMed Web of Science ®Google Scholar
• Xia S, Wang C, Postma EL, et al. Fibronectin 1 promotes migration and invasion of papillary thyroid cancer and predicts papillary thyroid cancer lymph node metastasis. Onco Targets Ther. 2017;10:1743–1755.
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhao C, Ye Y, et al. High expression of fibronectin 1 indicates poor prognosis in gastric cancer. Oncol Lett. 2020;19(1):93–102.
   PubMed Web of Science ®Google Scholar
• Ye Y, Zhang R, Feng H. Fibronectin promotes tumor cells growth and drugs resistance through a CDC42-YAP-dependent signaling pathway in colorectal cancer. Cell Biol Int. 2020;44(9):1840–1849.
   PubMed Web of Science ®Google Scholar
• Schwarzbauer JE. Fibronectin: from gene to protein. Curr Opin Cell Biol. 1991;3(5):786–791.
   PubMed Web of Science ®Google Scholar
• Mao Y, Schwarzbauer JE. Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol. 2005;24(6):389–399.
   PubMed Web of Science ®Google Scholar
• Sechler JL, Corbett SA, Schwarzbauer JE. Modulatory roles for integrin activation and the synergy site of fibronectin during matrix assembly. Mol Biol Cell. 1997;8(12):2563–2573.
   PubMed Web of Science ®Google Scholar
• Wilson CB, Leopard J, Cheresh DA, et al. Extracellular matrix and integrin composition of the normal bladder wall. World J Urol. 1996;14 Suppl 1:S30–S37.
   PubMed Web of Science ®Google Scholar
• Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002;115(20):3861–3863.
   PubMed Web of Science ®Google Scholar
• Lenselink EA. Role of fibronectin in normal wound healing. Int Wound J. 2015;12(3):313–316.
   PubMed Web of Science ®Google Scholar
• George EL, Georges-Labouesse EN, Patel-King RS, et al. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development. 1993;119(4):1079–1091.
   PubMed Web of Science ®Google Scholar
• Vaheri A, Kurkinen M, Lehto VP, et al. Codistribution of pericellular matrix proteins in cultured fibroblasts and loss in transformation: fibronectin and procollagen. Proc Natl Acad Sci USA. 1978;75(10):4944–4948.
   PubMed Web of Science ®Google Scholar
• Kahn P, Shin SI. Cellular tumorigenicity in nude mice. Test of associations among loss of cell-surface fibronectin, anchorage independence, and tumor-forming ability. J Cell Biol. 1979;82(1):1–16.
   PubMed Web of Science ®Google Scholar
• Chen LB, Gallimore PH, McDougall JK. Correlation between tumor induction and the large external transformation sensitive protein on the cell surface. Proc Natl Acad Sci USA. 1976;73(10):3570–3574.
   PubMed Web of Science ®Google Scholar
• Stenman S, Vaheri A. Fibronectin in human solid tumors. Int J Cancer. 1981;27(4):427–435.
   PubMed Web of Science ®Google Scholar
• Cheng HC, Abdel-Ghany M, Elble RC, et al. Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J Biol Chem. 1998;273(37):24207–24215.
   PubMed Web of Science ®Google Scholar
• Clark EA, Golub TR, Lander ES, et al. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000;406(6795):532–535.
   PubMed Web of Science ®Google Scholar
• Steffens S, Schrader AJ, Vetter G, et al. Fibronectin 1 protein expression in clear cell renal cell carcinoma. Oncol Lett. 2012;3(4):787–790.
   PubMed Web of Science ®Google Scholar
• Li Y, Miao L, Yu M, et al. α1-antitrypsin promotes lung adenocarcinoma metastasis through upregulating fibronectin expression. Int J Oncol. 2017;50(6):1955–1964.
   PubMed Web of Science ®Google Scholar
• Kenny HA, Chiang CY, White EA, et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014;124(10):4614–4628.
   PubMed Web of Science ®Google Scholar
• Yi W, Xiao E, Ding R, et al. High expression of fibronectin is associated with poor prognosis, cell proliferation and malignancy via the NF-κB/p53-apoptosis signaling pathway in colorectal cancer. Oncol Rep. 2016;36(6):3145–3153.
   PubMed Web of Science ®Google Scholar
• Hegele A, Heidenreich A, Kropf J, et al. Plasma levels of cellular fibronectin in patients with localized and metastatic renal cell carcinoma. Tumor Biol. 2004;25(3):111–116.
   PubMedGoogle Scholar
• Saito N, Nishimura H, Kameoka S. Clinical significance of fibronectin expression in colorectal cancer. Mol Med Rep. 2008;1(1):77–81.
   PubMed Web of Science ®Google Scholar
• Yu M, Ting DT, Stott SL, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012;487(7408):510–513.
   PubMed Web of Science ®Google Scholar
• Xiao J, Yang W, Xu B, et al. Expression of fibronectin in esophageal squamous cell carcinoma and its role in migration. BMC Cancer. 2018;18(1):976.
   PubMedGoogle Scholar
• Gao W, Liu Y, Qin R, et al. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line. Biochem Biophys Res Commun. 2016;476(1):35–41.
   PubMed Web of Science ®Google Scholar
• Schwarzbauer JE. Alternative splicing of fibronectin: three variants, three functions. Bioessays. 1991;13(10):527–533.
   PubMed Web of Science ®Google Scholar
• To WS, Midwood KS. Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair. 2011;4:21.
   PubMedGoogle Scholar
• Kumra H, Reinhardt DP. Fibronectin-targeted drug delivery in cancer. Adv Drug Deliv Rev. 2016;97:101–110.
   PubMed Web of Science ®Google Scholar
• White ES, Baralle FE, Muro AF. New insights into form and function of fibronectin splice variants. J Pathol. 2008;216(1):1–14.
   PubMed Web of Science ®Google Scholar
• Matsumoto E, Yoshida T, Kawarada Y, et al. Expression of fibronectin isoforms in human breast tissue: production of extra domain A+/extra domain B + by cancer cells and extra domain A + by stromal cells. Jpn J Cancer Res. 1999;90(3):320–325.
   PubMedGoogle Scholar
• Oyama F, Hirohashi S, Sakamoto M, et al. Coordinate oncodevelopmental modulation of alternative splicing of fibronectin pre-messenger RNA at ED-A, ED-B, and CS1 regions in human liver tumors. Cancer Res. 1993;53(9):2005–2011.
   PubMed Web of Science ®Google Scholar
• Pujuguet P, Hammann A, Moutet M, et al. Expression of fibronectin ED-A + and ED-B + isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumor-associated myofibroblasts. Am J Pathol. 1996;148(2):579–592.
   PubMed Web of Science ®Google Scholar
• Frey K, Fiechter M, Schwager K, et al. Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp Dermatol. 2011;20(8):685–688.
   PubMed Web of Science ®Google Scholar
• Ohnishi T, Hiraga S, Izumoto S, et al. Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Clin Exp Metastasis. 1998;16(8):729–741.
   PubMed Web of Science ®Google Scholar
• Sauer S, Erba PA, Petrini M, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009;113(10):2265–2274.
   PubMed Web of Science ®Google Scholar
• Schwager K, Villa A, Rösli C, et al. A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol. 2011;3:25.
   PubMedGoogle Scholar
• Wu J, Wang Y, Xu X, et al. Transcriptional activation of FN1 and IL11 by HMGA2 promotes the malignant behavior of colorectal cancer. Carcinogenesis. 2016;37(5):511–521.
   PubMed Web of Science ®Google Scholar
• Wei PL, Kuo LJ, Huang MT, et al. Nicotine enhances colon cancer cell migration by induction of fibronectin. Ann Surg Oncol. 2011;18(6):1782–1790.
   PubMed Web of Science ®Google Scholar
• Topalovski M, Brekken RA. Matrix control of pancreatic cancer: new insights into fibronectin signaling. Cancer Lett. 2016;381(1):252–258.
   PubMed Web of Science ®Google Scholar
• Huang S, Chakrabarty S. Regulation of fibronectin and laminin receptor expression, fibronectin and laminin secretion in human colon cancer cells by transforming growth factor-beta 1. Int J Cancer. 1994;57(5):742–746.
   PubMed Web of Science ®Google Scholar
• Schmidt R, Streit M, Kaiser R, et al. De novo expression of the alpha5beta1-fibronectin receptor in HT29 colon- cancer cells reduces activity of C-SRC. Increase of C-SRC activity by attachment on fibronectin. Int J Cancer. 1998;76(1):91–98.
   PubMed Web of Science ®Google Scholar
• DE Wever O, Sobczak-Thépot J, Vercoutter-Edouart A-S, et al. Priming and potentiation of DNA damage response by fibronectin in human colon cancer cells and tumor-derived myofibroblasts. Int J Oncol. 2011;39(2):393–400.
   PubMed Web of Science ®Google Scholar
• Huang CR, Lee CT, Chang KY, et al. Down-regulation of ARNT promotes cancer metastasis by activating the fibronectin/integrin β1/FAK axis. Oncotarget. 2015;6(13):11530–11546.
   PubMedGoogle Scholar
• Ding J, Li D, Wang X, et al. Fibronectin promotes invasiveness and focal adhesion kinase tyrosine phosphorylation of human colon cancer cell. Hepatogastroenterology. 2008;55(88):2072–2076.
   PubMedGoogle Scholar
• Ou J, Deng J, Wei X, et al. Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells. Stem Cell Res. 2013;11(2):820–833.
   PubMed Web of Science ®Google Scholar
• Ou J, Peng Y, Deng J, et al. Endothelial cell-derived fibronectin extra domain A promotes colorectal cancer metastasis via inducing epithelial-mesenchymal transition. Carcinogenesis. 2014;35(7):1661–1670.
   PubMed Web of Science ®Google Scholar
• Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019;35(3):347–367.
   PubMed Web of Science ®Google Scholar
• Bourdoulous S, Orend G, MacKenna DA, et al. Fibronectin matrix regulates activation of RHO and CDC42 GTPases and cell cycle progression. J Cell Biol. 1998;143(1):267–276.
   PubMed Web of Science ®Google Scholar
• Mukai M, Togawa A, Imamura F, et al. Sustained tyrosine-phosphorylation of FAK through Rho-dependent adhesion to fibronectin is essential for cancer cell migration. Anticancer Res. 2002;22(6a):3175–3184.
   PubMed Web of Science ®Google Scholar
• Ou J, Li J, Pan F, et al. Endostatin suppresses colorectal tumor-induced lymphangiogenesis by inhibiting expression of fibronectin extra domain A and integrin α9. J Cell Biochem. 2011;112(8):2106–2114.
   PubMed Web of Science ®Google Scholar
• Xiang L, Xie G, Ou J, et al. The extra domain A of fibronectin increases VEGF-C expression in colorectal carcinoma involving the PI3K/AKT signaling pathway. PLoS One. 2012;7(4):e35378.
   PubMed Web of Science ®Google Scholar
• Ruiz-Garcia E, Scott V, Machavoine C, et al. Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening. Br J Cancer. 2010;102(3):462–468.
   PubMed Web of Science ®Google Scholar
• Wunderlich H, Reichelt O, Zermann DH, et al. Fetal fibronectin: a new screening-marker for bladder cancer? Oncol Rep. 2001;8(3):669–672.
   PubMed Web of Science ®Google Scholar
• Dong F, Shen Y, Xu T, et al. Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis. World J Surg Oncol. 2018;16(1):61.
   PubMedGoogle Scholar
• Menéndez V, Fernández-Suárez A, Galán JA, et al. Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology. 2005;65(2):284–289.
   PubMed Web of Science ®Google Scholar
• Arnold SA, Loomans HA, Ketova T, et al. Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. Clin Exp Metastasis. 2016;33(1):29–44.
   PubMed Web of Science ®Google Scholar
• Futyma K, Kubiatowski T, Rózyńska K, et al. Decreased osteonectin and fibronectin gene expression in endometrial cancer cancer as a prognostic marker. Ginekol Pol. 2009;80(12):907–913.
   PubMed Web of Science ®Google Scholar
• Choate JJ, Mosher DF. Fibronectin concentration in plasma of patients with breast cancer, colon cancer, and acute leukemia. Cancer. 1983;51(6):1142–1147.
   PubMed Web of Science ®Google Scholar
• Haglund C, Ylätupa S, Mertaniemi P, et al. Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA. Br J Cancer. 1997;76(6):777–783.
   PubMed Web of Science ®Google Scholar
• Kida H, Takano Y, Yamamoto K, et al. A single nucleotide polymorphism in fibronectin 1 determines tumor shape in colorectal cancer. Oncol Rep. 2014;32(2):548–552.
   PubMed Web of Science ®Google Scholar
• Niknami Z, Eslamifar A, Emamirazavi A, et al. The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumor malignancy in colorectal carcinoma. Excli J. 2017;16:1009–1017.
   PubMed Web of Science ®Google Scholar
• Liang XY, Wang T, Yang XD, et al.[A study on correlation of hepatic metastasis of colorectal cancer to vascular endothelial growth factor, angiopoietin-2, and fibronectin]. Zhonghua Wei Chang Wai ke za Zhi. 2005;8(1):20–23. Chinese.
   PubMedGoogle Scholar
• Inufusa H, Nakamura M, Adachi T, et al. Localization of oncofetal and normal fibronectin in colorectal cancer. Correlation with histologic grade, liver metastasis, and prognosis. Cancer. 1995;75(12):2802–2808.
   PubMed Web of Science ®Google Scholar
• Viana L. d S, Affonso RJ, Silva SRM, et al. Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination. Oncology. 2013;84(2):81–91.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989;74(1):19–25.
   PubMed Web of Science ®Google Scholar
• Abdel-Ghany M, Cheng H, Levine RA, et al. Truncated dipeptidyl peptidase IV is a potent anti-adhesion and anti-metastasis peptide for rat breast cancer cells. Invasion Metastasis. 1998;18(1):35–43.
   PubMedGoogle Scholar
• Wang YJ, Lin JF, Cheng LH, et al. Pterostilbene prevents AKT-ERK axis-mediated polymerization of surface fibronectin on suspended lung cancer cells independently of apoptosis and suppresses metastasis. J Hematol Oncol. 2017;10(1):72.
   PubMedGoogle Scholar
• Chang YH, Lee SH, Liao IC, et al. Secretomic analysis identifies alpha-1 antitrypsin (A1AT) as a required protein in cancer cell migration, invasion, and pericellular fibronectin assembly for facilitating lung colonization of lung adenocarcinoma cells. Mol Cell Proteomics. 2012;11(11):1320–1339.
   PubMed Web of Science ®Google Scholar
• Borsi L, Castellani P, Allemanni G, et al. Preparation of phage antibodies to the ED-A domain of human fibronectin. Exp Cell Res. 1998;240(2):244–251.
   PubMed Web of Science ®Google Scholar
• Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer. 2006;118(6):1331–1339.
   PubMed Web of Science ®Google Scholar
• Rybak JN, Roesli C, Kaspar M, et al. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res. 2007;67(22):10948–10957.
   PubMed Web of Science ®Google Scholar
• Bootz F, Neri D. Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. Drug Discov Today. 2016;21(1):180–189.
   PubMed Web of Science ®Google Scholar
• Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res: Official J Am Assoc Cancer Res. 2003;9(2):571–579.
   PubMed Web of Science ®Google Scholar
• Moschetta M, Pretto F, Berndt A, et al. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res. 2012;72(7):1814–1824.
   PubMed Web of Science ®Google Scholar
• Hutmacher C, Gonzalo Nunez N, Liuzzi AR, et al. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells. Cancer Immunol Res. 2019;7(4):572–583.
   PubMed Web of Science ®Google Scholar
• Carnemolla B, Neri D, Castellani P, et al. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer. 1996;68(3):397–405.
   PubMed Web of Science ®Google Scholar
• Carnemolla B, Borsi L, Balza E, et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood. 2002;99(5):1659–1665.
   PubMed Web of Science ®Google Scholar
• Spitaleri G, Berardi R, Pierantoni C, et al. Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. J Cancer Res Clin Oncol. 2013;139(3):447–455.
   PubMed Web of Science ®Google Scholar
• El-Emir E, Dearling JL, Huhalov A, et al. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models. Br J Cancer. 2007;96(12):1862–1870.
   PubMed Web of Science ®Google Scholar
• Ou JJ, Wu F, Liang HJ. Colorectal tumor derived fibronectin alternatively spliced EDA domain exserts lymphangiogenic effect on human lymphatic endothelial cells. Cancer Biol Ther. 2010;9(3):186–191.
   PubMed Web of Science ®Google Scholar
• Fujita M, Ito-Fujita Y, Iyoda T, et al. Peptide TNIIIA2 derived from tenascin-C contributes to malignant progression in colitis-associated colorectal cancer via β1-integrin activation in fibroblasts. IJMS. 2019;20(11):2752.
   Google Scholar
• Garg A, Kokkoli E. pH-Sensitive PEGylated liposomes functionalized with a fibronectin-mimetic peptide show enhanced intracellular delivery to colon cancer cell. Curr Pharm Biotechnol. 2011;12(8):1135–1143.
   PubMed Web of Science ®Google Scholar
• Ranjbar L, Maleki F, Sadeghzadeh N, et al. In vitro/in vivo assessment of the targeting ability of[99mTc] Tc-labeled an aptide specific to the extra domain B of fibronectin (APTEDB) for colorectal cancer. Ann Nucl Med. 2020;34(7):460–466.
   PubMed Web of Science ®Google Scholar
• Ye F, Wu X, Jeong EK, et al. A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI. Bioconjug Chem. 2008;19(12):2300–2303.
   PubMed Web of Science ®Google Scholar